{
  "id": "601efda31cb411341a000069",
  "type": "yesno",
  "question": "Does bleomycin cause lung toxicity?",
  "ideal_answer": "Pulmonary toxicity is a devastating complication of bleomycin chemotherapy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26834240",
    "http://www.ncbi.nlm.nih.gov/pubmed/30464999",
    "http://www.ncbi.nlm.nih.gov/pubmed/17034512",
    "http://www.ncbi.nlm.nih.gov/pubmed/12771616",
    "http://www.ncbi.nlm.nih.gov/pubmed/7679525",
    "http://www.ncbi.nlm.nih.gov/pubmed/29269387",
    "http://www.ncbi.nlm.nih.gov/pubmed/83311",
    "http://www.ncbi.nlm.nih.gov/pubmed/15992893",
    "http://www.ncbi.nlm.nih.gov/pubmed/1696541",
    "http://www.ncbi.nlm.nih.gov/pubmed/6192740",
    "http://www.ncbi.nlm.nih.gov/pubmed/27241272",
    "http://www.ncbi.nlm.nih.gov/pubmed/1689606",
    "http://www.ncbi.nlm.nih.gov/pubmed/30398042",
    "http://www.ncbi.nlm.nih.gov/pubmed/1711838",
    "http://www.ncbi.nlm.nih.gov/pubmed/6167758",
    "http://www.ncbi.nlm.nih.gov/pubmed/28121640",
    "http://www.ncbi.nlm.nih.gov/pubmed/32079853",
    "http://www.ncbi.nlm.nih.gov/pubmed/27190828",
    "http://www.ncbi.nlm.nih.gov/pubmed/6165468",
    "http://www.ncbi.nlm.nih.gov/pubmed/21602446",
    "http://www.ncbi.nlm.nih.gov/pubmed/2425242",
    "http://www.ncbi.nlm.nih.gov/pubmed/10783125",
    "http://www.ncbi.nlm.nih.gov/pubmed/9806661",
    "http://www.ncbi.nlm.nih.gov/pubmed/25951185",
    "http://www.ncbi.nlm.nih.gov/pubmed/25026360",
    "http://www.ncbi.nlm.nih.gov/pubmed/2413151",
    "http://www.ncbi.nlm.nih.gov/pubmed/2582337",
    "http://www.ncbi.nlm.nih.gov/pubmed/31809714",
    "http://www.ncbi.nlm.nih.gov/pubmed/7679991",
    "http://www.ncbi.nlm.nih.gov/pubmed/33647319",
    "http://www.ncbi.nlm.nih.gov/pubmed/26888428",
    "http://www.ncbi.nlm.nih.gov/pubmed/28185527",
    "http://www.ncbi.nlm.nih.gov/pubmed/30755913",
    "http://www.ncbi.nlm.nih.gov/pubmed/1690503",
    "http://www.ncbi.nlm.nih.gov/pubmed/24195693",
    "http://www.ncbi.nlm.nih.gov/pubmed/2443992",
    "http://www.ncbi.nlm.nih.gov/pubmed/31673206",
    "http://www.ncbi.nlm.nih.gov/pubmed/2449257",
    "http://www.ncbi.nlm.nih.gov/pubmed/6205617",
    "http://www.ncbi.nlm.nih.gov/pubmed/30902828"
  ],
  "snippets": [
    {
      "text": "bleomycin-induced pulmonary fibrosis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31809714",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "bleomycin (BLM)-induced pulmonary ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31809714",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pulmonary toxicity is a devastating complication of bleomycin chemotherapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28121640",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bleomycin containing regimen is routinely employed in the treatment of HL. Pulmonary toxicity due to this drug is the most feared side effect in these regimens where the mortality rate is approximately 2%-3%. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31673206",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bleomycin might cause pulmonary fibrosis at higher cumulative doses as toxic effect directly to the lungs or most likely in addition by the formation of vascular microthrombi.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6167758",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The comparative pulmonary toxicity induced by bleomycin and talisomycin (former trivial name: tallysomycin A) was evaluated by measuring lung hydroxyproline content.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6165468",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinicians should always remember that bleomycin toxicity may lead to fatal complications in patients with comorbid conditions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30398042",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONTEXT: The application of bleomycin is limited due to its side effects including lung toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25026360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bleomycin is an antineoplastic agent that causes a dose-related lung fibrosis that limits its therapeutic effectiveness.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2413151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Acute Lung Toxicity After Intralesional Bleomycin Sclerotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29269387",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We report a case of a severe acute lung toxicity after a low dose of a second bleomycin intralesional injection in a 5-year-old girl.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29269387",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Renal damage, following cisplatin administration, with subsequent accumulation of bleomycin was the likely cause of the high lung toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1690503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Whenever possible, bleomycin should precede cisplatin infusion to minimize the risk of lung toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1690503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The most severe form of BLM-induced pulmonary toxicity is lung fibrosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26888428",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results from this study suggest that an excess production of superoxide anions by alveolar macrophages may be the underlying cause of bleomycin pulmonary toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2425242",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bleomycin lung toxicity is well established and can manifest as bleomycin-induced pneumonitis, but pneumomediastinum and pneumothorax are very rare complications.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30755913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "High doses of bleomycin administered to patients with lymphomas and other tumors lead to significant lung toxicity in general, and to apoptosis of epithelial cells, in particular. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25951185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "sis of bleomycin-induced lung toxicity is based on the combination of clinical and radiological features, and requires to rule out differential diagnoses including pneumocystis. \"Bleo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27241272",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Doxorubicin, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) is associated with severe toxicity in older patients, particularly from bleomycin-induced lung toxicity (BLT). Ther",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26834240",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "s studies have proposed that the lung toxicity caused by bleomycin is related to the C-terminal regions of these drugs, which have been shown to closely interact with DNA in metal-bleomycin-DNA complexes. Some o",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30464999",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES: Bleomycin, etoposide, and cisplatin (BEP) is the most common and successful chemotherapy regimen for germ-cell tumor (GCT) patients, accompanied by a bleomycin-induced dose-dependent lung toxicity in certain pat",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32079853",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e been no respiratory problems attributable to bleomycin lung toxicity in this study compared with four (3 associated with patient deaths) seen in 91 previously treated patients. The relat",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2449257",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mechanisms of bleomycin-induced lung damage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1711838",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Previous studies have proposed that the lung toxicity caused by bleomycin is related to the C-terminal regions of these drugs, which have been shown to closely interact with DNA in metal-bleomycin-DNA complexes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30464999",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "g V30 cutoff value of 32% was estimated.CONCLUSION: Bleomycin and RT may cause lung injury ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24195693",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Postmortem lung studies were performed in all six patients and revealed findings compatible with bleomycin-induced lung toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1690503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, the cytotoxic effects of bleomycin cause a number of adverse responses, in particular in the lung and the skin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17034512",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bleomycin, a widely used anti-cancer drug, may give rise to pulmonary fibrosis, a serious side effect which is associated with significant morbidity and mortality.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30902828",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bleomycin is a cancer therapeutic known to cause lung injury which progresses to fibrosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33647319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "and repair. Bleomycin pulmonary toxicity is mediated, at least in part, by the generation of active oxy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9806661",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This report suggests that bleomycin lung toxicity may be reversible if treated aggressively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7679525",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although all bleomycin-treated animals had some evidence of lung toxicity, histologic examination of the lungs revealed markedly reduced bleomycin toxicity in the rats exposed to hypoxia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6205617",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Low temperature inhibits bleomycin lung toxicity in the rat.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6192740",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Results at day 22, 3 wk after bleomycin treatment, showed that airway delivery of liposomes before and after intratracheal administration of bleomycin significantly reduced bleomycin-induced lung toxicity as evidenced by less body weight loss, chronic lung inflammation, and fibrosis as well as improved lung compliance compared with controls.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21602446",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Protective effect of hypoxia on bleomycin lung toxicity in the rat.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6205617",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "N-acetyl cysteine (NAC) has recently been shown to have antioxidant properties, and since bleomycin produces pulmonary damage via free oxygen radical toxicity, the possible protective effect of NAC on bleomycin lung toxicity was investigated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2582337",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "All rats treated with bleomycin only had typical changes of bleomycin lung toxicity whereas the animals treated with bleomycin and NAC had minimal pathology.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2582337",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "atic compliance on day 15 was severely decreased with bleomycin alone and showed a further significant decrease when granulocyte colony-stimulating factor was added (controls, 3.85 +/- 0.14 mL/kPa; bleomycin, 1.44 +/- 0.06 mL/kPa; and bleomycin + granulocyte colony-stimulating factor, 0.65 +/- 0.09 mL/kPa; control vs. bleomycin, p <.0001; and bleomycin vs. bleomycin + granulocyte colony-stimulating factor, p =.0003). Lung m",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12771616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bleomycin sometimes causes fatal pulmonary toxicity, including bleomycin-induced pneumonitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15992893",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bleomycin is an antineoplastic agent causing fatal pulmonary toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28185527",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pulmonary toxicity is an important adverse effect of bleomycin treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2443992",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pulmonary toxicity is the most significant complication of bleomycin administration.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1689606",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "It is possible, however, that the low incidence of clinically significant and fatal pulmonary toxicity, as experienced in this group of patients, may be related to the infusion of bleomycin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1689606",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bleomycin-mediated pulmonary toxicity: evidence for a p53-mediated response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10783125",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Occurrence of bleomycin lung toxicity requires an immediate and often permanent discontinuation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27241272",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "All three developed bleomycin induced pulmonary toxicity in the form of pulmonary fibrosis during treatment of the disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27190828",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "One of the fatal side effect of bleomycin is pulmonary toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27190828",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pulmonary Toxicity of Bleomycin - A Case Series from a Tertiary Care Center in Southern India.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27190828",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bleomycin is potentially capable of inducing a diffuse interstitial fibrosis of the lung, the pathogenesis of which has not yet been elucidated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/83311",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Intratracheal instillation of bleomycin 1.5 mg resulted in a severe pneumonitis with influx of inflammatory cells into the alveoli as assessed by alveolar lavage, oedema of the alveolar walls, and up to an eight fold increase in the total pulmonary extravascular albumin space, maximal at 72 hours.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2443992",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2443992",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bleomycin is a highly effective antitumor agent, but pulmonary toxicity, characterized by an acute inflammatory reaction and associated pulmonary edema, limits clinical use of the drug.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1696541",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this study we investigated bleomycin-induced pulmonary toxicity in patients with germ-cell tumour by means of technetium-99m diethylene triamine penta-acetic acid aerosol scintigraphy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7679991",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}